Market Cap 715.64M
Revenue (ttm) 579.12M
Net Income (ttm) 175.50M
EPS (ttm) N/A
PE Ratio 3.80
Forward PE N/A
Profit Margin 30.30%
Debt to Equity Ratio 0.00
Volume 486,900
Avg Vol 631,526
Day's Range N/A - N/A
Shares Out 224.34M
Stochastic %K 69%
Beta 2.48
Analysts Sell
Price Target $6.48

Latest News on CVAC

CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript

Apr 10, 2025, 12:59 PM EDT - 13 days ago

CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript


European Patent Office declares CureVac mRNA patent valid

Mar 27, 2025, 6:22 PM EDT - 27 days ago

European Patent Office declares CureVac mRNA patent valid


CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 3:08 PM EST - 5 months ago

CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript


GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

Jul 3, 2024, 10:18 AM EDT - 10 months ago

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

GSK


CureVac Announces Voting Results of General Meeting

Jun 24, 2024, 4:20 PM EDT - 10 months ago

CureVac Announces Voting Results of General Meeting


CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript

Apr 24, 2024, 3:12 PM EDT - 1 year ago

CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript


CureVac stock gains as COVID vaccine candidates show promise

Jan 5, 2024, 7:59 AM EST - 1 year ago

CureVac stock gains as COVID vaccine candidates show promise


CureVac N.V. (CVAC) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 3:15 PM EST - 1 year ago

CureVac N.V. (CVAC) Q3 2023 Earnings Call Transcript


CureVac signals progress on mRNA flu vaccine

Sep 12, 2023, 8:05 AM EDT - 1 year ago

CureVac signals progress on mRNA flu vaccine


CureVac's CVGBM Trial: Promising Results Progress Pipeline

Jul 24, 2023, 9:51 AM EDT - 1 year ago

CureVac's CVGBM Trial: Promising Results Progress Pipeline